Zynex Inc Shares Fall 55.3 Percent Following Chapter 11 Restructuring
Zynex, Inc. (NASDAQ:ZYXI) shares declined 55.3% to $0.29 on Dec 18, 2025, after the company announced it has entered Chapter 11 financial restructuring. The medical device manufacturer, which specializes in non-invasive technology, has secured new financing from its lenders to maintain operations during the reorganization process.
The restructuring is intended to stabilize the financial position of the company as it navigates a competitive and regulated healthcare sector. Investors can find more information regarding the company in the history mission ownership and mission vision documents. Detailed analysis of the company's current standing is available in the financial health report and the investor profile.
The decline in Zynex stock occurred amid broader market volatility that impacted several other equities and investment funds:
- Harding Loevner Institutional Emerging Markets Portfolio (HLMEX) fell 49.4%.
- Harding Loevner Emerging Markets Portfolio Advisor Class (HLEMX) declined 48.4%.
- Glenmede Women in Leadership US Eq (GWILX) dropped 48.3% to $8.79.
- SaverOne 2014 Ltd (SVRE) shares fell 46.6% to $1.89.
The restructuring of Zynex, Inc. (NASDAQ:ZYXI) highlights ongoing challenges within the medical technology industry. The company stated that the new financing from lenders is expected to support its efforts to strengthen its financial foundation while continuing to serve its patient base with non-invasive medical devices.
Zynex, Inc. (ZYXI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.